

Daniel Abramowicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5533510/publications.pdf>

Version: 2024-02-01

208
papers

10,081
citations

38742

50
h-index

38395

95
g-index

212
all docs

212
docs citations

212
times ranked

8744
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 810-816.	0.7	8
2	Assessment of pre-donation glomerular filtration rate: going back to basics. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 430-437.	0.7	7
3	Is the failure of recent trials on withdrawal of calcineurin inhibitors due to inadequate mycophenolic acid dosing?. <i>Journal of Nephrology</i> , 2022, , 1.	2.0	0
4	Waiting Time for Second Kidney Transplantation and Mortality. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 90-97.	4.5	16
5	mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 799-803.	0.7	13
6	MO1010: Seroconversion Rate After Primary Vaccination with Two Doses of BNT162B2 versus MRNA-1273 in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
7	The role of HLA-DP mismatches and donor specific HLA-DP antibodies in kidney transplantation: a case series. <i>Transplant Immunology</i> , 2021, 65, 101287.	1.2	15
8	5â€Year outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients. <i>Transplant International</i> , 2021, 34, 313-326.	1.6	1
9	A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological highâ€risk patients and a preâ€emptive strategy in intermediateâ€risk patients: Combining the best of two options?. <i>Transplant Infectious Disease</i> , 2021, 23, e13467.	1.7	7
10	Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial. <i>Clinical Microbiology and Infection</i> , 2021, 27, 398-405.	6.0	43
11	Long-term risks after kidney donation: how do we inform potential donors? A survey from DESCARTES and EKITA transplantation working groups. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1742-1753.	0.7	13
12	MO149PREGNANCY AFTER LIVING KIDNEY DONATION, A SYSTEMATIC REVIEW OF THE AVAILABLE EVIDENCE AND A REVIEW OF THE CURRENT GUIDANCE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
13	Renin-Angiotensin System Blockers and the Risk of COVID-19â€Related Mortality in Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1061-1072.	4.5	7
14	SARS-CoV-2 breakthrough infections in vaccinated kidney transplant recipients: an issue of concern. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2261-2262.	2.9	6
15	A surprising journey into the conversion of urinary protein creatinine ratio to urinary albumin creatinine ratio as needed in the Kidney Failure Risk Equation. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1481-1482.	2.9	5
16	Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 918-926.	0.7	16
17	New evidence shows it is time to stop unnecessary use of antibiotics in kidney transplant recipients with asymptomatic bacteriuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 754-756.	0.7	2
18	Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERA. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, i1-i15.	0.7	25

#	ARTICLE	IF	CITATIONS
19	The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 714-721.	0.7	61
20	Transplantation in older individuals: is it really better than dialysis?. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 86-91.	1.6	8
21	TO011HEALTH UTILITY BUT NOT UREMIC TOXINS ARE ASSOCIATED WITH ONE YEAR MORTALITY IN HD PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
22	Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis. <i>Transplant International</i> , 2020, 33, 1626-1642.	1.6	30
23	Frailty: a new comorbidity in kidney transplant candidates?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1085-1087.	0.7	4
24	Does Perioperative Patient Perfusion Obviate the Need for Kidney Machine Perfusion? A Retrospective Analysis of Patients Receiving a Kidney From Donation After Circulatory Death Donors. <i>Transplantation Proceedings</i> , 2020, 52, 2923-2929.	0.6	1
25	P1765COMBINING THE BEST OF TWO OPTIONS: A SPLIT STRATEGY WITH PROPHYLAXIS OR PRE-EMPTIVE THERAPY TO PREVENT CYTOMEGALOVIRUS AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
26	TO009THE POTENTIAL OF DONOR-DERIVED CELL-FREE DNA AS A BIOMARKER FOR REJECTION IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
27	P1611PRE-ANALYTICAL CONSIDERATIONS IN STUDYING CIRCULATING MICRORNA EXPRESSION: COMPARISON BETWEEN PAIRED EDTA PLASMA, EDTA WHOLE BLOOD AND PAXGENE BLOOD RNA TUBES. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
28	P1630IS THERE ALWAYS A SURVIVAL BENEFIT WITH KIDNEY TRANSPLANTATION? RESULTS FROM A BELGIAN COHORT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
29	How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 899-904.	0.7	96
30	TO005OPERATIONAL TOLERANCE IN KIDNEY TRANSPLANT RECIPIENTS: TOMOGRAM TRANSCRIPTOMIC STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
31	Variability in the incidence of renal replacement therapy over time in Western industrialized countries: A retrospective registry analysis. <i>PLoS ONE</i> , 2020, 15, e0235004.	2.5	5
32	FP252BETA TRACE PROTEIN IN ACUTE KIDNEY INJURY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
33	FP544THE EFFECT OF HAEMODIALYSIS AND HAEMODIAFILTRATION ON PLASMA LEVELS OF MICRORNA. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
34	Standard work-up of the low-risk kidney transplant candidate: a European expert survey of the ERA-EDTA Developing Education Science and Care for Renal Transplantation in European States Working Group. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1605-1611.	0.7	12
35	Prevalence of asymptomatic bacteriuria among kidney transplant recipients beyond two months post-transplant: A multicenter, prospective, cross-sectional study. <i>PLoS ONE</i> , 2019, 14, e0221820.	2.5	11
36	Management of Asymptomatic Bacteriuria After Kidney Transplantation: What Is the Quality of the Evidence Behind the Infectious Diseases Society of America Guidelines?. <i>Clinical Infectious Diseases</i> , 2019, 70, 987-988.	5.8	3

#	ARTICLE	IF	CITATIONS
37	Cardiovascular disease in kidney transplant recipients: leave no stone unturned. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 727-730.	0.7	2
38	Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 2252-2261.	4.7	24
39	Pre-existing malignancies in renal transplant candidates—time to reconsider waiting times. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1292-1300.	0.7	15
40	MicroRNAs in AKI and Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 454-468.	4.5	58
41	Host and microbial factors in kidney transplant recipients with <i>Escherichia coli</i> acute pyelonephritis or asymptomatic bacteriuria: a prospective study using whole-genome sequencing. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 878-885.	0.7	12
42	Electrolytes disturbances after kidney transplantation. <i>Acta Clinica Belgica</i> , 2019, 74, 48-52.	1.2	14
43	What happens to the live donor in the years following donation?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1289-1291.	0.7	0
44	Reply to Hernandez et al. - GWAS of acute renal graft rejection. <i>American Journal of Transplantation</i> , 2018, 18, 2098-2099.	4.7	5
45	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1661-1668.	0.7	32
46	Antibiotics for asymptomatic bacteriuria in kidney transplant recipients. <i>The Cochrane Library</i> , 2018, CD011357.	2.8	30
47	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 1726-1734.	4.7	47
48	Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board*. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1699-1707.	0.7	42
49	Outcomes of kidney transplantations in children weighing 15 kilograms or less: a retrospective cohort study. <i>Transplant International</i> , 2018, 31, 720-728.	1.6	21
50	Early steroid withdrawal: a niche for anti-interleukin 2 receptor monoclonal antibodies?. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1083-1087.	0.7	1
51	Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. <i>Acta Clinica Belgica</i> , 2018, 73, 80-89.	1.2	12
52	Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. <i>PLoS ONE</i> , 2018, 13, e0208207.	2.5	50
53	The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study. <i>Transplant Immunology</i> , 2018, 50, 55-59.	1.2	22
54	Non-invasive Biomarkers of Acute Rejection in Kidney Transplantation: Novel Targets and Strategies. <i>Frontiers in Medicine</i> , 2018, 5, 358.	2.6	62

#	ARTICLE	IF	CITATIONS
55	Genome-Wide Association Study of Acute Renal Graft Rejection. American Journal of Transplantation, 2017, 17, 201-209.	4.7	50
56	Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?. American Journal of Transplantation, 2017, 17, 22-27.	4.7	62
57	Unacceptable human leucocyte antigens: how to navigate between increased immunological risk and waiting time?. Nephrology Dialysis Transplantation, 2017, 32, 745-747.	0.7	5
58	Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. Nephrology Dialysis Transplantation, 2017, 32, 216-223.	0.7	79
59	TOO20SHOULD WE DISCONTINUE CYCLOSPORIN OR STEROIDS IN RENAL TRANSPLANTATION? FIVE YEAR OUTCOME RESULTS OF THE CISTCERT TRIAL. Nephrology Dialysis Transplantation, 2017, 32, iii86-iii86.	0.7	0
60	Optimizing hypertension management in renal transplantation. Journal of Hypertension, 2017, 35, 2335-2338.	0.5	5
61	Analysis of the Profile of Live Kidney Donation Candidates in the Antwerp University Hospital. Transplantation, 2017, 101, S96.	1.0	0
62	Outcome of the Assessment of Live Kidney Donation Candidates in the Antwerp University Hospital. Transplantation, 2017, 101, S137.	1.0	0
63	Optimizing hypertension management in renal transplantation: a call to action. Nephrology Dialysis Transplantation, 2017, 32, 1959-1962.	0.7	14
64	Does Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality donor kidneys?. Nephrology Dialysis Transplantation, 2017, 32, 1934-1938.	0.7	17
65	Composing a new song for trials: the Standardized Outcomes in Nephrology (SONG) initiative. Nephrology Dialysis Transplantation, 2017, 32, 1963-1966.	0.7	50
66	MP794THE KIDNEY DONOR RISK INDEX: A HELPFUL TOOL IN ALLOCATING DISEASED DONOR KIDNEYS?. Nephrology Dialysis Transplantation, 2017, 32, iii725-iii726.	0.7	0
67	Prediction of delayed graft function using different scoring algorithms: A single-center experience. World Journal of Transplantation, 2017, 7, 260-268.	1.6	9
68	SO002QUANTIFICATION OF PLASMA DONOR-DERIVED CELL-FREE DNA TO MONITOR KIDNEY TRANSPLANT HEALTH: PRELIMINARY RESULTS OF A SINGLE TUBE MULTIPLEX PCR ASSAY. Nephrology Dialysis Transplantation, 2016, 31, i1-i1.	0.7	2
69	Criteria for and Appropriateness of Renal Transplantation in Elderly Patients With End-Stage Renal Disease. Transplantation, 2016, 100, e55-e65.	1.0	63
70	Immunosuppression in the elderly renal allograft recipient: a systematic review. Transplantation Reviews, 2016, 30, 144-153.	2.9	25
71	MO031IS THE INCIDENCE OF RENAL REPLACEMENT THERAPY IN WESTERNIZED COUNTRIES DECLINING?. Nephrology Dialysis Transplantation, 2016, 31, i40-i41.	0.7	0
72	Old Habits Die Hard: Screening for and Treating Asymptomatic Bacteriuria After Kidney Transplantation. American Journal of Transplantation, 2016, 16, 3301-3302.	4.7	6

#	ARTICLE	IF	CITATIONS
73	Single-Center Case Series of Donor-Related Malignancies: Rare Cases With Tremendous Impact. <i>Transplantation Proceedings</i> , 2016, 48, 2669-2677.	0.6	5
74	Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 319-323.	2.9	6
75	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1002-1013.	0.7	46
76	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 691-697.	0.7	62
77	Cell-Free DNA: An Upcoming Biomarker in Transplantation. <i>American Journal of Transplantation</i> , 2015, 15, 2541-2551.	4.7	142
78	Delayed Graft Function in Kidney Transplants: Time Evolution, Role of Acute Rejection, Risk Factors, and Impact on Patient and Graft Outcome. <i>Journal of Transplantation</i> , 2015, 2015, 1-9.	0.5	37
79	SaO017NANTES-DESCARTES INITIATIVE ON OPERATIONAL TOLERANCE AFTER KIDNEY TRANSPLANTATION: A EUROPE-WIDE SURVEY AND NETWORK. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii30-iii31.	0.7	0
80	FP847WHAT IS THE PREDICTIVE VALUE OF DELAYED GRAFT FUNCTION CALCULATORS IN KIDNEY TRANSPLANTATION?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii360-iii361.	0.7	0
81	SP007GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NEW LOCI ASSOCIATED WITH ACUTE RENAL GRAFT REJECTION. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii383-iii383.	0.7	0
82	Strategies to increase the donor pool and access to kidney transplantation: an international perspective. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 217-222.	0.7	68
83	Renal transplantation in the elderly. <i>Transplantation Reviews</i> , 2015, 29, 191-192.	2.9	7
84	Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study. <i>American Journal of Transplantation</i> , 2015, 15, 1923-1932.	4.7	50
85	Is the Kidney Donor Risk Index a step forward in the assessment of deceased donor kidney quality?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1285-1290.	0.7	54
86	Do elderly recipients really benefit from kidney transplantation?. <i>Transplantation Reviews</i> , 2015, 29, 197-201.	2.9	20
87	European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care: FIGURE 1. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1790-1797.	0.7	229
88	Does basiliximab induction trigger lifethreatening ARDS and shock in young patients after kidney transplantation?. <i>Clinical Nephrology</i> , 2015, 83 (2015), 61-70.	0.7	2
89	UMOD polymorphism rs12917707 is not associated with severe or stable IgA nephropathy in a large Caucasian cohort. <i>BMC Nephrology</i> , 2014, 15, 138.	1.8	2
90	Professor Dr Yves Vanrenterghem. <i>Transplantation</i> , 2014, 97, 125-126.	1.0	0

#	ARTICLE	IF	CITATIONS
91	Should we treat asymptomatic bacteriuria after renal transplantation?. Nephrology Dialysis Transplantation, 2014, 29, 260-262.	0.7	31
92	Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study. Nephrology Dialysis Transplantation, 2014, 29, 463-466.	0.7	11
93	Antibiotics for asymptomatic bacteriuria in kidney transplant recipients. The Cochrane Library, 2014, , .	2.8	1
94	European renal best practice guideline on the management and evaluation of the kidney donor and recipient. Nefrologia, 2014, 34, 293-301.	0.4	20
95	Guideline. Nephrology Dialysis Transplantation, 2013, 28, ii1-ii71.	0.7	93
96	Large decrease of anti-tetanus anatoxin and anti-pneumococcal antibodies at one year after renal transplantation. Clinical Nephrology, 2013, 79, 313-317.	0.7	12
97	Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation. Therapeutic Drug Monitoring, 2012, 34, 143-147.	2.0	23
98	Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study. Nephrology Dialysis Transplantation, 2012, 27, 2547-2553.	0.7	23
99	Shipping donor kidneys within Eurotransplant: outcomes after renal transplantation in a single-centre cohort study. Nephrology Dialysis Transplantation, 2012, 27, 3638-3644.	0.7	7
100	The Once-Daily Formulation of Tacrolimus. Transplantation, 2012, 93, 241-243.	1.0	22
101	Posttransplant Major Histocompatibility Complex Class I Chain-Related Gene A Antibodies and Long-Term Graft Outcomes in a Multicenter Cohort of 779 Kidney Transplant Recipients. Transplantation, 2012, 93, 1258-1264.	1.0	32
102	New-Onset Diabetes After Renal Transplantation. Diabetes Care, 2012, 35, 181-188.	8.6	105
103	Kidney donation after circulatory death in a country with a high number of brain dead donors: 10-year experience in Belgium. Transplant International, 2012, 25, 857-866.	1.6	23
104	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrology Dialysis Transplantation, 2011, 26, 2099-2106.	0.7	77
105	42-P Biological and clinical relevance of the luminex crossmatch: A single center study of 117 kidney transplant recipients. Human Immunology, 2011, 72, S45.	2.4	0
106	Laparoscopic-Assisted Recipient Nephrectomy and Recipient Kidney Procurement during Orthotopic Living-Related Kidney Transplantation. Case Reports in Transplantation, 2011, 2011, 1-4.	0.3	1
107	Conversion From Prograf to Advagraf Among Kidney Transplant Recipients Results in Sustained Decrease in Tacrolimus Exposure. Transplantation, 2011, 91, 566-569.	1.0	64
108	FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrology Dialysis Transplantation, 2011, 26, 3802-3805.	0.7	44

#	ARTICLE	IF	CITATIONS
109	Ineligibility for renal transplantation: prevalence, causes and survival in a consecutive cohort of 445 patients. <i>Clinical Transplantation</i> , 2011, 25, 576-583.	1.6	21
110	Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. <i>Transplant Infectious Disease</i> , 2011, 13, 397-406.	1.7	49
111	Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2700-2705.	0.7	31
112	Influenza A/H1N1 Vaccine in Patients Treated by Kidney Transplant or Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2573-2578.	4.5	67
113	Extended Valganciclovir Prophylaxis in D+/Râ™ Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study. <i>Transplantation</i> , 2010, 90, 1427-1431.	1.0	175
114	Major Histocompatibility Complex Class 1 Chain-Related Antigen A Antibodies: Sensitizing Events and Impact on Renal Graft Outcomes. <i>Transplantation</i> , 2010, 90, 168-174.	1.0	47
115	Thrombophilic Factors Do Not Predict Outcomes in Renal Transplant Recipients Under Prophylactic Acetylsalicylic Acid. <i>American Journal of Transplantation</i> , 2010, 10, 99-105.	4.7	14
116	Bortezomib: a new player in pre- and post-transplant desensitization?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3480-3489.	0.7	33
117	Genotypeâ€™ phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. <i>Kidney International</i> , 2010, 77, 443-449.	5.2	117
118	The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 213-221.	2.9	7
119	Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1385-1392.	6.1	177
120	TCF7L2 Polymorphism Associates with New-Onset Diabetes after Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2459-2467.	6.1	63
121	Late Onset of Bladder Urothelial Carcinoma After Kidney Transplantation for End-Stage Aristolochic Acid Nephropathy: A Case Series With 15-Year Follow-up. <i>American Journal of Kidney Diseases</i> , 2008, 51, 471-477.	1.9	99
122	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2162-2166.	0.7	59
123	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 719-727.	0.7	41
124	Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3727-3729.	0.7	20
125	HLA Mismatches Remain Risk Factors for Acute Kidney Allograft Rejection in Patients Receiving Quadruple Immunosuppression With Anti-Interleukin-2 Receptor Antibodies. <i>Transplantation</i> , 2008, 85, 411-416.	1.0	42
126	Cold Ischemia is a Major Determinant of Acute Rejection and Renal Graft Survival in the Modern Era of Immunosuppression. <i>Transplantation</i> , 2008, 85, S3-S9.	1.0	143

#	ARTICLE	IF	CITATIONS
127	Immunomodulators: interleukins, interferons, and IV immunoglobulin. , 2008, , 683-698.		0
128	Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis. Journal of the American Society of Nephrology: JASN, 2007, 18, 2180-2188.	6.1	973
129	Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications. Transplant International, 2007, 21, 071012050800003-???.	1.6	36
130	Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transplant International, 2007, 21, 071029080703003-???.	1.6	50
131	Laparoscopic Live Donor Right Nephrectomy: A New Technique to Maximize the Length of the Renal Vein Using a Modified Endo GIA Stapler. European Urology, 2007, 51, 1326-1331.	1.9	46
132	Effect of Atorvastatin Therapy and Conversion to Tacrolimus on Hypercholesterolemia and Endothelial Dysfunction After Renal Transplantation. Transplantation, 2006, 82, 771-778.	1.0	29
133	IL-4 Deficiency Prevents Eosinophilic Rejection and Uncovers a Role for Neutrophils in the Rejection of MHC Class II Disparate Skin Grafts. Transplantation, 2005, 80, 1485-1492.	1.0	29
134	Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Clinical Transplantation, 2005, 19, 475-482.	1.6	22
135	A Controlled Study of Vitamin D3 to Prevent Bone Loss in Renal-Transplant Patients Receiving Low Doses of Steroids. Transplantation, 2005, 79, 108-115.	1.0	100
136	Cyclosporine Withdrawal from a Mycophenolate Mofetilâ€œContaining Immunosuppressive Regimen: Results of a Five-Year, Prospective, Randomized Study. Journal of the American Society of Nephrology: JASN, 2005, 16, 2234-2240.	6.1	139
137	Conversion From Tacrolimus to Cyclosporin Is Associated With a Significant Improvement of Glucose Metabolism in Patients With New-Onset Diabetes Mellitus After Renal Transplantation. Transplantation Proceedings, 2005, 37, 1857-1860.	0.6	24
138	A novel mutation of tumor necrosis factor receptor alpha type 1 associated with TRAPS and amyloidosis. American Journal of Medical Genetics Part A, 2004, 128A, 331-331.	2.4	3
139	Amplification of T-cell responses by neutrophils: relevance to allograft immunity. Immunology Letters, 2004, 94, 163-166.	2.5	18
140	Prevalence and Management of Anemia in Renal Transplant Recipients: A European Survey. American Journal of Transplantation, 2003, 3, 835-845.	4.7	281
141	A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1. Transplantation, 2003, 75, 844-851.	1.0	150
142	Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric antiâ€œinterleukin-2 receptor monoclonal antibody basiliximab. Transplantation, 2003, 76, 459-463.	1.0	77
143	Immunomodulators: interleukins, interferons, and the OKT3 monoclonal antibody. , 2003, , 459-482.		0
144	Skin Graft Rejection Elicited by Î²2-Microglobulin as a Minor Transplantation Antigen Involves Multiple Effector Pathways: Role of Fas-Fas Ligand Interactions and Th2-Dependent Graft Eosinophil Infiltrates. Journal of Immunology, 2002, 169, 500-506.	0.8	22

#	ARTICLE	IF	CITATIONS
145	Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study ^{1,2} . <i>Transplantation</i> , 2002, 74, 1725-1734.	1.0	118
146	Multiple pathways to allograft rejection. <i>Transplantation</i> , 2002, 73, 1373-1381.	1.0	190
147	Critical role of interleukin 5 and eosinophils in concanavalin A-induced hepatitis in mice. <i>Gastroenterology</i> , 2002, 122, 2001-2010.	1.3	64
148	Hypereosinophilic syndrome induced by neonatal immunization against MHC class II alloantigen: critical role of IL-4. <i>European Journal of Immunology</i> , 2002, 32, 174-181.	2.9	7
149	Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. <i>Kidney International</i> , 2002, 61, 354-355.	5.2	14
150	A role for eosinophils in transplant rejection. <i>Trends in Immunology</i> , 2001, 22, 247-251.	6.8	104
151	Autosomal-dominant periodic fever with AA amyloidosis: Novel mutation in tumor necrosis factor receptor 1 gene Rapid Communication. <i>Kidney International</i> , 2001, 59, 1677-1682.	5.2	39
152	HYPERCHOLESTEROLEMIA AND CHRONIC REJECTION OF RENAL ALLOGRAFTS. <i>Transplantation</i> , 2001, 72, 752-753.	1.0	0
153	Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1993-1999.	0.7	158
154	Urothelial Carcinoma Associated with the Use of a Chinese Herb (<i>Aristolochia fangchi</i>). <i>New England Journal of Medicine</i> , 2000, 342, 1686-1692.	27.0	944
155	SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS ¹² . <i>Transplantation</i> , 2000, 69, 1252-1260.	1.0	499
156	IMPAIRED ANTIGEN-PRESENTING CELL FUNCTION CONTRIBUTES TO T-CELL HYPORESPONSIVENESS IN STABLE LUNG TRANSPLANT RECIPIENTS ¹ . <i>Transplantation</i> , 2000, 69, 1332-1336.	1.0	3
157	HYPERCHOLESTEROLEMIA IS ASSOCIATED WITH INCREASED KIDNEY GRAFT LOSS CAUSED BY CHRONIC REJECTION IN MALE PATIENTS WITH PREVIOUS ACUTE REJECTION. <i>Transplantation</i> , 2000, 70, 464-472.	1.0	108
158	Kidney graft dysfunction after drug interaction between miocamycin and cyclosporin. <i>Transplant International</i> , 1999, 12, 157-157.	1.6	1
159	Induction protocols: yesterday, today, and tomorrow. <i>Transplantation Proceedings</i> , 1999, 31, 1100-1101.	0.6	6
160	CD3 ANTIBODY-INDUCED IL-10 IN RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1999, 68, 616-622.	1.0	13
161	DOWN-REGULATION OF INTERLEUKIN-2 AND INTERFERON- γ AND MAINTENANCE OF INTERLEUKIN-4 AND INTERLEUKIN-10 PRODUCTION AFTER ADMINISTRATION OF AN ANTI-CD3 MONOCLONAL ANTIBODY IN MICE ¹ . <i>Transplantation</i> , 1999, 68, 677-684.	1.0	11
162	Induction with anti-CD3 antibodies. <i>Current Opinion in Organ Transplantation</i> , 1999, 4, 312.	1.6	6

#	ARTICLE	IF	CITATIONS
163	Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. <i>Journal of Clinical Investigation</i> , 1999, 103, 1659-1667.	8.2	103
164	Experience with the Wujciak-Opelz allocation system in a single center: an increase in HLA-DR mismatching and in early occurring acute rejection episodes. <i>Transplant International</i> , 1998, 11, 378-381.	1.6	8
165	IL-12 prevents neonatal induction of transplantation tolerance in mice. <i>European Journal of Immunology</i> , 1998, 28, 1426-1430.	2.9	45
166	REACTIVATION OF HEPATITIS B AFTER TRANSPLANTATION IN PATIENTS WITH PRE-EXISTING ANTI-HEPATITIS B SURFACE ANTIGEN ANTIBODIES. <i>Transplantation</i> , 1998, 66, 883-886.	1.0	104
167	CHRONIC REJECTION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-DISPARATE SKIN GRAFTS AFTER ANTI-CD3 THERAPY. <i>Transplantation</i> , 1998, 66, 1537-1544.	1.0	9
168	OKT3 Nephrotoxicity: From acute tubular necrosis to hemolytic uremic syndrome. , 1998, , 301-309.		0
169	HHV-8 is associated with recurrent Kaposi's sarcoma in a renal transplant recipient. <i>Transplant International</i> , 1997, 10, 81-82.	1.6	5
170	ABSENCE OF DELETERIOUS EFFECT ON LONG-TERM KIDNEY GRAFT SURVIVAL OF REJECTION EPISODES WITH COMPLETE FUNCTIONAL RECOVERY ¹ . <i>Transplantation</i> , 1997, 63, 1739-1743.	1.0	75
171	A PILOT TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-10 IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING OKT3 INDUCTION THERAPY ^{1,2} . <i>Transplantation</i> , 1997, 64, 999-1006.	1.0	46
172	Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: A pilot study in Chinese herbs nephropathy. <i>American Journal of Kidney Diseases</i> , 1996, 27, 209-215.	1.9	93
173	HHV-8 is associated with recurrent Kaposi's sarcoma in a renal transplant recipient. <i>Transplant International</i> , 1996, 10, 81-82.	1.6	1
174	CD40 engagement induces monocyte procoagulant activity through an interleukin-10 resistant pathway. <i>European Journal of Immunology</i> , 1996, 26, 3048-3054.	2.9	36
175	OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival. <i>Kidney International</i> , 1996, 49, 768-772.	5.2	49
176	THE IgE HUMORAL RESPONSE IN OKT3-TREATED PATIENTS. <i>Transplantation</i> , 1996, 61, 577-581.	1.0	22
177	RENAL TRANSPLANTATION EXPOSES PATIENTS WITH PREVIOUS KAPOSI'S SARCOMA TO A HIGH RISK OF RECURRENCE ¹ . <i>Transplantation</i> , 1996, 62, 463-466.	1.0	45
178	EFFICACY OF REJECTION PROPHYLAXIS WITH OKT3. <i>Transplantation</i> , 1996, 62, 700,701.	1.0	1
179	INFLUENCE OF DONOR-RECIPIENT HLA-DR MISMATCHES AND OKT3 PROPHYLAXIS ON CADAVER KIDNEY GRAFT SURVIVAL. <i>Transplantation</i> , 1995, 60, 253-257.	1.0	20
180	Inability of OKT3 to prevent donor-derived ABO hemolytic anemia in a kidney-pancreas transplant recipient. <i>Transplant International</i> , 1995, 8, 159-160.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Soluble tumor necrosis factor-receptors are not a useful marker of acute allograft rejection: a study in patients with renal or cardiac allografts. <i>Transplant International</i> , 1995, 8, 459-465.	1.6	4
182	The induction of human T cell unresponsiveness by soluble anti-CD3 mAb requires T cell activation. <i>International Immunology</i> , 1995, 7, 1593-1598.	4.0	15
183	The Use of OKT3 in Clinical Transplantation. <i>Medical Intelligence Unit</i> , 1995, , 99-135.	0.2	1
184	Soluble tumor necrosis factor-receptors are not a useful marker of acute allograft rejection: a study in patients with renal or cardiac allografts. <i>Transplant International</i> , 1995, 8, 459-465.	1.6	4
185	CRITICAL ROLE OF INTERLEUKIN 4 IN THE INDUCTION OF NEONATAL TRANSPLANTATION TOLERANCE. <i>Transplantation</i> , 1995, 59, 1571-1575.	1.0	75
186	Inability of OKT3 to prevent donor-derived ABO hemolytic anemia in a kidney-pancreas transplant recipient. <i>Transplant International</i> , 1995, 8, 159-160.	1.6	0
187	CRITICAL ROLE OF INTERLEUKIN 4 IN THE INDUCTION OF NEONATAL TRANSPLANTATION TOLERANCE. <i>Transplantation</i> , 1995, 59, 1571-1575.	1.0	3
188	Interleukin-10 controls interferon- γ and tumor necrosis factor production during experimental endotoxemia. <i>European Journal of Immunology</i> , 1994, 24, 1167-1171.	2.9	295
189	In Vivo Immunosuppression Induced by a Weakly Mitogenic Antibody to Mouse CD3: Evidence That Induction of Long-Lasting in Vivo Unresponsiveness Requires TcR Signaling. <i>Cellular Immunology</i> , 1994, 157, 239-248.	3.0	6
190	High-dose glucocorticosteroids increase the procoagulant effects of OKT3. <i>Kidney International</i> , 1994, 46, 1596-1602.	5.2	28
191	EFFECTS OF SYSTEMIC ADMINISTRATION OF rIL-10 IN AN IN VIVO MODEL OF ALLOREACTIVITY. <i>Transplantation</i> , 1994, 58, 972-974.	1.0	19
192	MODULATION OF THE RELEASE OF CYTOKINES AND REDUCTION OF THE SHOCK SYNDROME INDUCED BY ANTI-CD3 MONOCLONAL ANTIBODY IN MICE BY INTERLEUKIN-10. <i>Transplantation</i> , 1994, 57, 1436-1439.	1.0	32
193	OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. <i>Transplant International</i> , 1994, 7, 258-263.	1.6	3
194	MODULATION OF THE RELEASE OF CYTOKINES AND REDUCTION OF THE SHOCK SYNDROME INDUCED BY ANTI-CD3 MONOCLONAL ANTIBODY IN MICE BY INTERLEUKIN-10. <i>Transplantation</i> , 1994, 57, 1436-1439.	1.0	1
195	Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. <i>European Journal of Immunology</i> , 1993, 23, 2700-2703.	2.9	97
196	Procoagulant effect of the OKT3 monoclonal antibody: Involvement of tumor necrosis factor. <i>Kidney International</i> , 1992, 42, 1124-1129.	5.2	31
197	EVIDENCE THAT PENTOXIFYLLINE REDUCES ANTI-CD3 MONOCLONAL ANTIBODY-INDUCED CYTOKINE RELEASE SYNDROME. <i>Transplantation</i> , 1991, 52, 674-679.	1.0	64
198	Renal immunopathology in murine host-versus-graft disease. <i>Kidney International</i> , 1991, 40, 852-861.	5.2	16

#	ARTICLE	IF	CITATIONS
199	Intraperitoneal Secretion of Interleukin-6 during Continuous Ambulatory Peritoneal Dialysis. <i>Nephron</i> , 1990, 56, 277-280.	1.8	79
200	Increased expression of Ia antigens on B cells after neonatal induction of lymphoid chimerism in mice: Role of interleukin 4. <i>European Journal of Immunology</i> , 1990, 20, 469-476.	2.9	31
201	Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: Role of tumor necrosis factor. <i>European Journal of Immunology</i> , 1990, 20, 707-710.	2.9	83
202	Persistence of anti-donor allohelper T cells after neonatal induction of allotolerance in mice. <i>European Journal of Immunology</i> , 1990, 20, 1647-1653.	2.9	38
203	OKT3-INDUCED CYTOKINE RELEASE ATTENUATION BY HIGH-DOSE METHYLPREDNISOLONE. <i>Lancet</i> , The, 1989, 334, 802-803.	13.7	31
204	Increased serum levels of endopeptidase 24.11 (â€œenkephalinaseâ€œ) in patients with end-stage renal failure. <i>Life Sciences</i> , 1989, 45, 133-141.	4.3	27
205	POSSIBLE NEPHROTOXICITY OF THE PROPHYLACTIC USE OF OKT3 MONOCLONAL ANTIBODY AFTER CADAVERIC RENAL TRANSPLANTATION. <i>Transplantation</i> , 1989, 48, 524-525.	1.0	22
206	RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN-2, AND GAMMA-INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1989, 47, 606-608.	1.0	327
207	CHIMERISM AND CYTOTOXIC T LYMPHOCYTE UNRESPONSIVENESS AFTER NEONATAL INJECTION OF SPLEEN CELLS IN MICE EFFECTS OF T CELL DEPLETION AND OF A SEMIALLOGENEIC OR FULLY ALLOGENEIC INOCULUM. <i>Transplantation</i> , 1987, 44, 696-700.	1.0	13
208	Timing of the Pre-Transplant Workup for Renal Transplantation: Is There Room for Improvement?. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	0